Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probiotics are **live microorganisms**—primarily certain bacteria (*Lactobacillus*, *Bifidobacterium*, *Streptococcus*, *Enterococcus*, *Escherichia*) and some yeasts (*Saccharomyces boulardii*)—that confer health benefits to the host when administered in adequate amounts. They are not a single molecule or receptor but rather a broad category encompassing many different microbial species and strains. Their primary recognized benefit is supporting gastrointestinal health by modulating the composition and activity of the gut microbiota. Mechanistically, probiotics can outcompete harmful microbes for resources or attachment sites; enhance mucosal barrier function; produce metabolites that inhibit pathogens; modulate immune responses; reduce inflammation; regulate oxidative stress via activation of cellular antioxidant pathways; influence cell proliferation/apoptosis signaling relevant to cancer prevention/supportive care. The specific effects depend on genus/species/strain identity as well as host factors. **Note:** "Probiotics" is not a canonical therapeutic target like an enzyme or receptor—it refers to whole living organisms used therapeutically. Therefore, *is_target* should be **false**, and *is_incorrect* should be **true** because "probiotic" does not refer to a discrete molecular entity suitable for structured drug-target mapping per standard pharmacological conventions.
Probiotics act through several mechanisms including: - Competing with pathogenic microbes for nutrients and binding sites on the gut epithelium. - Strengthening the intestinal barrier by promoting mucous secretion and tight junction integrity. - Modulating host immune responses via interaction with pattern recognition receptors such as toll-like receptors. - Producing antimicrobial compounds like organic acids and bacteriocins to inhibit pathogen growth. - Regulating signaling pathways involved in inflammation and cell survival such as NF-kB, MAPK, Nrf2/ARE pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probiotic microorganism.